• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

December 8, 2021

Study Shows Higher BTKi-Related Toxicity Burden with Ibrutinib, Lower Impact of CV-Related Toxicity with Acalabrutinib

Author(s):

Jill Murphy, Associate Editor
Conference|ASH Annual Meeting and Exposition - American Society of Hematology Annual Meeting and Exposition

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

A phase 3 trial of acalabrutinib versus ibrutinib demonstrated efficacy and improved tolerability with acalabrutinib in previously treated chronic lymphocytic leukemia (CLL), according to a session presented at the American Society of Hematology Annual Meeting & Exposition 2021.1

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy. It is also currently indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to an AstraZeneca press release.2

During the study, a major objective of the investigators was to assess the risk-benefit of quality-adjusted time without symptoms or toxicity in relapsed or refractory CLL.2

The patients received oral acalabrutinib 100 mg or ibrutinib 420 mg until disease progression or unacceptable toxicity, with the overall toxicity, exposure-adjusted incidence, and exposure-adjusted time with event durations were assessed for the most common BTKi-related adverse events (AEs). Additionally, atrial fibrillation, hypertension, and bleeding events were further characterized by time to onset, cumulative incidence by Kaplan-Meier method, patient subgroup, and AE management.1

The results showed that out of 533 randomized patients, incidences of any-grade afib/flutter, hypertension, and bleeding were statistically higher with ibrutinib, with higher exposure-adjusted incidence and exposure-adjusted time with event. Further, cases of any-grade diarrhea, arthralgia, contusion, UTI, back pain, muscle spasms, and dyspepsia were statistically higher with ibrutinib, whereas cases of headache and cough were statistically higher with acalabrutinib.1

In terms of any-grade hypertension, the median time to onset was similar for acalabrutinib and ibrutinib, but cumulative incidence was lower for acalabrutinib at 6 months, 12 months, 18 months, and 24 months. Hypertension occurred less frequently with acalabrutinib versus ibrutinib in subgroups of age, prior line of therapy, and among patients without prior history. There was no dose reductions or treatment discontinuations due to hypertension occurred in either arm, and concomitant medication use for hypertension was less common acalabrutinib versus ibrutinib.1

As for any-grade bleeding events, they occurred less frequently with acalabrutinib versus ibrutinib in most subgroups of age and prior line of therapy. Additionally, bleeding events were associated with dose reduction in 3 versus 2 patients in the acalabrutinib versus ibrutinib arms, respectively, leading to treatment discontinuation in 2 versus 4 patients.1

REFERENCES

  1. Seymour JF, Byrd JC, Hillmen P, et al. Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Presented at: American Society of Hematology Annual Meeting and Exposition. December 13, 2021 [virtual].
  2. AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021. BusinessWire. November 5, 2021. Accessed December 13, 2021. https://www.businesswire.com/news/home/20211105005227/en/AstraZeneca-Advances-Ambition-to-Redefine-Care-for-Blood-Cancer-at-ASH-2021

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Pharmacist and doctor -- Image credit: ake1150 | stock.adobe.com
Pharmacist and patient -- Image credit: Zamrznuti tonovi | stock.adobe.com
Type 1 diabetes -- Image credit: daniiD | stock.adobe.com
Related Content
Advertisement
Close up isolated image of a doctor holding a tape measure in her hands which shows 40 inches as abdominal circumference upper limit in healthy people. Concept for weigh loss and fitness. | Image Credit: Grandbrothers | stock.adobe.com
August 15th 2025

PFAS Exposure Tied to Greater Weight Regain After Adolescent Bariatric Surgery

Danielle Valletti, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
August 15th 2025

Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

Alexandra Gerlach, Associate Editor Kevin Chen, PharmD Amanda Cass, PharmD, BCPS, BCOP
Chest pain illness causing heart attck and stroke risk in woman patient with doctor examing and diagnosing patient health in hospital clinic | Image Credit: Chinnapong | stock.adobe.com
August 15th 2025

FDA Officials Near Decision on Aficamten for Obstructive Hypertrophic Cardiomyopathy

Danielle Valletti, Assistant Editor
A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025
August 15th 2025

A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP
Acalabrutinib capsules | Image Credit: © luchschenF - stock.adobe.com
August 15th 2025

Acalabrutinib Demonstrates Improved Safety, Survival to Chemoimmunotherapy in CLL

Alexandra Gerlach, Associate Editor
Sickle cell disease (SCD) -- Image credit: tussik | stock.adobe.com
August 15th 2025

BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease

Gillian McGovern, Associate Editor
Related Content
Advertisement
Close up isolated image of a doctor holding a tape measure in her hands which shows 40 inches as abdominal circumference upper limit in healthy people. Concept for weigh loss and fitness. | Image Credit: Grandbrothers | stock.adobe.com
August 15th 2025

PFAS Exposure Tied to Greater Weight Regain After Adolescent Bariatric Surgery

Danielle Valletti, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
August 15th 2025

Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

Alexandra Gerlach, Associate Editor Kevin Chen, PharmD Amanda Cass, PharmD, BCPS, BCOP
Chest pain illness causing heart attck and stroke risk in woman patient with doctor examing and diagnosing patient health in hospital clinic | Image Credit: Chinnapong | stock.adobe.com
August 15th 2025

FDA Officials Near Decision on Aficamten for Obstructive Hypertrophic Cardiomyopathy

Danielle Valletti, Assistant Editor
A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025
August 15th 2025

A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP
Acalabrutinib capsules | Image Credit: © luchschenF - stock.adobe.com
August 15th 2025

Acalabrutinib Demonstrates Improved Safety, Survival to Chemoimmunotherapy in CLL

Alexandra Gerlach, Associate Editor
Sickle cell disease (SCD) -- Image credit: tussik | stock.adobe.com
August 15th 2025

BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.